https://www.live-feeds.com/feed/novo-nordisk-raises-2026-outlook-as-q3-obesity-sales-jump-22Continuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-nordisk-raises-2026-outlook-as-q3-obesity-sales-jump-22https://www.live-feeds.com/feed/novo-nordisk-raises-2026-outlook-as-q3-obesity-sales-jump-22#u188539Mon, 09 Nov 2026 17:45:39 +0000Novo Nordisk raised its 2026 financial outlook and beat third-quarter profit forecasts with 27% growth, driven by soaring demand for its obesity treatments. Third-quarter obesity sales jumped 22%, bolstered by strong performance from the Wegovy pill and Ozempic. The Danish drugmaker saw its shares climb following the earnings release, as executives reported that the Wegovy pill exceeded expectations. The market response reflects high investor enthusiasm for the company's weight-loss portfolio despite broader market pressures.Why it mattersThe pharmaceutical giant continues to capitalize o